Navellier & Associates Inc Eli Lilly & CO Transaction History

Navellier & Associates Inc

$805 Million
Q1 2024

A detailed history of Navellier & Associates Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Navellier & Associates Inc holds 25,605 shares of LLY stock, worth $23.2 Million. This represents 2.48% of its overall portfolio holdings.

Number of Shares

25,605

Previous 24,106 6.22%

Holding current value

$23.2 Million

Previous $14.1 Million 41.76%

% of portfolio

2.48%

Previous 2.13%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$592.2 - $792.28 $887,707 - $1.19 Million	1,499 Added 6.22%	25,605 $19.9 Million
Q4 2023 Feb 08, 2024	BUY	$525.19 - $619.13 $1.18 Million - $1.4 Million	2,254 Added 10.31%	24,106 $14.1 Million
Q3 2023 Nov 09, 2023	BUY	$434.7 - $599.3 $3.97 Million - $5.47 Million	9,125 Added 71.7%	21,852 $11.7 Million
Q2 2023 Aug 07, 2023	SELL	$350.74 - $468.98 $106,624 - $142,569	-304 Reduced 2.33%	12,727 $5.97 Million
Q1 2023 May 12, 2023	SELL	$310.63 - $364.82 $1.15 Million - $1.36 Million	-3,718 Reduced 22.2%	13,031 $4.48 Million

Q4 2022 Feb 02, 2023	SELL	$321.55 - $374.67 $275,889 - $321,466	-858 Reduced 4.87%	16,749 $6.13 Million
Q3 2022 Nov 09, 2022	SELL	$296.48 - $337.87 $108,808 - $123,998	-367 Reduced 2.04%	17,607 $5.69 Million
Q2 2022 Aug 12, 2022	BUY	$278.73 - $327.27 $5.01 Million - $5.88 Million	17,974 New	17,974 $5.83 Million
Q2 2021 Aug 09, 2021	SELL	$180.55 - $233.54 $361,100 - $467,080	-2,000 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$164.32 - $212.72 $16,432 - $21,272	-100 Reduced 4.76%	2,000 $374,000
Q2 2020 Aug 12, 2020	SELL	$136.42 - $164.18 $13,641 - $16,418	-100 Reduced 4.55%	2,100 $345,000
Q1 2020 May 13, 2020	BUY	$119.05 - $147.35 $23,810 - $29,470	200 Added 10.0%	2,200 $305,000
Q4 2019 Feb 12, 2020	BUY	$106.92 - $132.43 $21,384 - $26,486	200 Added 11.11%	2,000 $263,000
Q3 2019 Oct 16, 2019	SELL	$106.79 - $116.16 $10,679 - $11,616	-100 Reduced 5.26%	1,800 $201,000
Q2 2019 Jul 17, 2019	BUY	$110.79 - $129.32 $11,079 - $12,932	100 Added 5.56%	1,900 $211,000
Q1 2019 May 15, 2019	SELL	$111.31 - $131.02 $11,131 - $13,102	-100 Reduced 5.26%	1,800 $234,000
Q4 2018 Jan 15, 2019	SELL	$105.9 - $118.64 $24,357 - $27,287	-230 Reduced 10.8%	1,900 $220,000
Q3 2018 Nov 14, 2018	SELL	$85.86 - $107.31 $23,182 - $28,973	-270 Reduced 11.25%	2,130 $229,000
Q2 2018 Aug 06, 2018	BUY	$75.7 - $86.88 $181,680 - $208,512	2,400 New	2,400 $205,000
Q1 2018 May 21, 2018	SELL	$74.21 - $87.6 $260,625 - $307,651	-3,512 Closed	0 $0
Q4 2017 Feb 12, 2018	SELL	$81.94 - $87.89 $548,998 - $588,863	-6,700 Reduced 65.61%	3,512 $297,000
Q3 2017 Nov 14, 2017	SELL	$77.07 - $85.54 $415,253 - $460,889	-5,388 Reduced 34.54%	10,212 $874,000
Q2 2017 Aug 24, 2017	BUY	N/A	15,600	15,600 $1.28 Million

Others Institutions Holding LLY

# of Institutions

3,719

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $860B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Navellier & Associates Inc with notifications on news.

Account

Navellier & Associates Inc Eli Lilly & CO Transaction History